Wave Life Sciences, Duchenne muscular dystrophy
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
Wave Life Sciences Ltd. (NASDAQ:WVE) revealed interim data from the ongoing Phase 2 FORWARD-53 study of WVE-N531 for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. DMD is a genetic disease that causes progressive muscle weakness and degeneration caused by a mutation in the dystrophin gene.
Just as F1 teams rely on real-time data to optimize performance, IoT is enabling life sciences manufacturers to achieve new ...
Former Fed chairman Alan Greenspan coined the phrase "irrational exuberance" to describe the risk of unduly escalated asset ...
Here's why Chicago is expected to be a growth spot for life sciences in the coming years. Chicago is expected to be a ...
GlobalData on MSN1d
ReAlta Life Sciences doses first patient in trial of graft-versus-host disease drugThe primary goals of the study are to evaluate the safety and overall response rate in patients who are given RLS-0071.
Five life sciences companies are expanding their operations in Connecticut, including several that are leasing space in the ...
By engaging with some of the most influential executives in the industry and the many organizations that advocate for them, the series will provide valuable perspectives on the evolving landscape of ...
Swiss anti-aging biotech Rejuveron is seeking its rejuvenation as it morphs into Centenara Labs. | Swiss anti-aging biotech ...
Marama Labs, a life-sciences instrumentation start-up, has secured €280,000 in funding from Enterprise Ireland to fund the ...
Projects focus on cancer therapies, robotic clot removal catheters, and mRNA vaccines, among other technologies ...
Klick Health today announced the round two results of its $1,000,000 Klick Prize after awarding a combined $200,000 to four ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback